Brazil’s health regulator greenlights trials of new Chinese vaccine

PUBLISHED: Mon, 19 Apr 2021 14:30:00 GMT

SAO PAULO, April 19 (Reuters) – Brazilian health regulator Anvisa has authorized clinical trials of a new COVID vaccine developed by China’s Sichuan Clover Biopharmaceuticals, according to a statement on Monday.

Anvisa said the company was authorized to conduct Phase II and III trials in Brazil. Sichuan Clover is planning to test the vaccine on 22,000 volunteers in Latin America, South Africa, Belgium, China, Spain, Poland and United Kingdom.

(Reporting by Eduardo Simoes, writing by Carolina Mandl; Editing by Kirsten Donovan)

(c) Copyright Thomson Reuters 2021. Click For Restrictions –

Sign Up for Our Newsletter Daily Update
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent.
Get this delivered to your inbox, and more info about about our products and services. By signing up for newsletters, you are agreeing to our Terms of Use and Privacy Policy.